## Policy Statement

Initial or repeat bone mineral density (BMD) measurement is not indicated unless the results will influence treatment decisions.

An initial measurement of central (hip or spine) BMD using dual x-ray absorptiometry may be considered medically necessary to assess fracture risk and the need for pharmacologic therapy in both women and men who are considered at risk for osteoporosis. BMD testing may be indicated under any of the following conditions:

- Women age 65 and older, regardless of other risk factors
- Men age 70 and older, regardless of other risk factors
- Younger postmenopausal women about whom there is a concern based on their risk factors
- Men age 50 to 70 about whom there is a concern based on their risk factors
- Adults with a condition or taking a medication associated with low bone mass or bone loss

Repeat measurement of central (hip or spine) BMD using dual x-ray absorptiometry for individuals who previously tested normal (does not require pharmacologic treatment) may be considered medically necessary at an interval not more frequent than every 3 to 5 years; the interval depends on patient risk factors.

Regular (not more frequent than every 2 to 3 years) serial measurements of central (hip or spine) BMD using dual x-ray absorptiometry to monitor treatment response may be considered medically necessary when the information will affect treatment decisions such as duration of therapy.

Peripheral (DXA) BMD testing may be considered medically necessary for either of the following indications:

- When conventional central (hip or spine) DXA screening is not feasible
- In the management of hyperparathyroidism, where peripheral DXA at the forearm (i.e., radius) is essential for evaluation

BMD measurement using ultrasound densitometry, quantitative computed tomography, or dual x-ray absorptiometry of peripheral sites is considered investigational except as noted above.

## Policy Guidelines

The decision to perform bone density assessment should be based on an individual’s fracture risk profile and skeletal health assessment. In addition to age, gender, and BMD, risk factors included in the World Health Organization Fracture Risk Assessment (FRAX) Tool are:

- Low body mass index;
- Parental history of hip fracture;
- Previous fragility fracture in adult life (i.e., occurring spontaneously or a fracture arising from trauma which, in a healthy individual, would not have resulted in a fracture);
- Current smoking or alcohol 3 or more units/day, where a unit is equivalent to a standard glass of beer (285 mL), a single measure of spirits (30 mL), a medium-sized glass of wine (120 mL), or 1 measure of an aperitif (60 mL);
- A disorder strongly associated with osteoporosis. These include rheumatoid arthritis, type I (insulin dependent) diabetes, osteogenesis imperfecta in adults, untreated
long-standing hyperthyroidism, hypogonadism or premature menopause (less than 45 years), chronic malnutrition or malabsorption, and chronic liver disease;

- Current exposure to oral glucocorticoids or the patient has been exposed to oral glucocorticoids for more than 3 months at a dose of prednisolone of 5 mg daily or more (or equivalent doses of other glucocorticoids).

A 2011 joint position statement from the International Society for Clinical Densitometry and the International Osteoporosis Foundation includes the official position that FRAX with BMD predicts risk of fracture better than clinical risk factors or BMD alone. In addition, the joint position statement states that measurements other than BMD or T score at the femoral neck by DXA are not recommended for use with FRAX.

The FRAX tool does not include a recommendation about which patients to further assess or treat. The FRAX website states that this is a matter of clinical judgment and recommendations may vary by country. The FRAX calculation tool can be accessed at the following address: https://www.shef.ac.uk/FRAX/tool.jsp.

National Osteoporosis Foundation

The 2014 Clinician's Guide to Prevention and Treatment of Osteoporosis published by the National Osteoporosis Foundation (NOF, 2014) has identified the following medical conditions and medications as risk factors for osteoporosis-related fracture:

Genetic Factors
- Cystic fibrosis
- Homocystinuria
- Osteogenesis imperfecta
- Ehlers-Danlos
- Hypophosphatasia
- Parental history of hip fracture
- Gaucher's disease
- Porphyria
- Glycogen storage diseases
- Marfan syndrome
- Riley-Day syndrome
- Hemochromatosis
- Menkes steely hair syndrome

Hypogonadal States
- Androgen insensitivity
- Hyperprolactinemia
- Turner's & Klinefelter's syndromes
- Anorexia nervosa and bulimia
- Panhypopituitarism
- Athletic amenorrhea
- Premature ovarian failure

Endocrine Disorders
- Central Obesity
- Diabetes mellitus
- Thyrotoxicosis
- Cushing's syndrome
- Hyperparathyroidism

Gastrointestinal Disorders
- Celiac disease
- Inflammatory bowel disease
6.01.01  Bone Mineral Density Studies

- Primary biliary cirrhosis
- Gastric bypass
- Malabsorption
- GI surgery
- Pancreatic disease

Hematologic Disorders
- Hemophilia
- Multiple myeloma
- Systemic mastocytosis
- Leukemia and lymphomas
- Sickle cell disease
- Thalassemia
- Monoclonal gammopathies

Rheumatic and Autoimmune Diseases
- Ankylosing spondylitis
- Lupus
- Rheumatoid arthritis

Neurological and musculoskeletal risk factors
- Epilepsy
- Multiple sclerosis
- Muscular dystrophy
- Parkinson’s disease
- Spinal cord injury
- Stroke

Miscellaneous Conditions and Diseases
- Alcoholism
- Emphysema
- Muscular dystrophy
- Amyloidosis
- End-stage renal disease
- Parenteral nutrition
- Chronic metabolic acidosis
- Epilepsy
- Post-transplant bone disease
- Congestive heart failure
- Idiopathic scoliosis
- Prior fracture as an adult
- Depression
- Multiple sclerosis
- Sarcoidosis
- Low body weight

Medications
- Aluminum (in antacids)
- Anticoagulants (heparin)
- Anticonvulsants
- Aromatase inhibitors
- Barbiturates
- Cancer chemotherapeutic drugs
- Depo-medroxyprogesterone (premenopausal contraception)
- Glucocorticoids (greater than or equal to 5 mg/day of prednisone or equivalent for three months)
• Gonadotropin releasing hormone agonists
• Lithium cyclosporine A and tacrolimus
• Methotrexate
• Parenteral nutrition
• Proton pump inhibitors
• Selective serotonin reuptake inhibitors
• Taxotrexifen (premenopausal use)
• Thiazolidinediones (such as Actos® and Avandia®)
• Thyroid hormones (in excess)

**Bone Mineral Density (BMD) Technologies**

Ultrasound densitometry is an office-based technology. As discussed further in the Rationale section, it is unknown whether this technology can be used to predict response to pharmacologic therapy (i.e., reduce fractures).

Dual x-ray absorptiometry (DXA) of axial central sites (i.e., hip and spine) is the most commonly used technique, but peripheral (appendicular) DXA and quantitative computed tomography (QCT) scanning are sometimes used, based on local availability. Peripheral measurement can identify patients with low bone mass but does not predict response to pharmacologic therapy and is not a substitute for central DXA measurements. Therefore, central DXA (hip or spine) is required for both the initial diagnosis and repeat bone mineral density (BMD) assessments.

Peripheral measurement of BMD may be appropriate:
• If the hip/spine or hip/hip cannot be done or the patient is over the table limit for weight;
• Hyperparathyroidism, where the forearm is essential for diagnosis.

In pediatric patients, total body calcium is preferred because it helps reduce following patients with growing bones. This applies to pediatric patients who are not skeletally mature, as documented by nonclosure of growth plates (e.g., 15 years of age or younger).

**Coding**

The following CPT codes identify BMD testing technologies:

- **77078**: Computed tomography, bone mineral density study, 1 or more sites, axial skeleton (e.g., hips, pelvis, spine)
- **77080**: Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (e.g., hips, pelvis, spine)
- **77081**: Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; appendicular skeleton (peripheral) (e.g., radius, wrist, heel)
- **76977**: Ultrasound bone density measurement and interpretation, peripheral site(s), any method

Single- and dual-photon absorptiometry are now rarely used and may be considered obsolete. The CPT codes for these techniques are:

- **78350**: Bone density (bone mineral content) study, 1 or more sites; single photon absorptiometry
- **78351**: Bone density (bone mineral content) study, 1 or more sites; dual photon absorptiometry, 1 or more sites

**Description**

Bone mineral density (BMD) studies can be used to identify individuals with osteoporosis and to monitor response to osteoporosis treatment, with the goal of reducing the risk of fracture. Bone density is most commonly evaluated with dual x-ray absorptiometry (DXA); other technologies are available.
Related Policies

- Bone Turnover Markers for the Diagnosis and Management of Osteoporosis and Diseases Associated With High Bone Turnover
- Vertebral Fracture Assessment With Densitometry

Benefit Application

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Some state or federal mandates [e.g., Federal Employee Program (FEP)] prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.

Regulatory Status

Several devices that measure bone density have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. Some examples include:

- QCT-Bone Mineral Phantom (Image Analysis) in 1985
- Quantitative Digital Radiography (QDR™; Hologic) x-ray bone densitometer using dual x-ray absorptiometry in 1987
- Lunar DPX bone densitometer (now GE Lunar DPX NT®; GE Healthcare) in 1988
- Accudxa® Bone Mineral Density Assessment System (Lone Oak Medical Technologies, Doylestown, PA) in 2012.

In addition, some ultrasound bone sonometers have been approved by the FDA through the premarket approval (PMA) process. One example is the Sahara® Clinical Bone Sonometer (Hologic), which received approval in March 1998. Its intended use is for quantitative ultrasound measurement of the calcaneus (heel bone), the results of which can be used in conjunction with other clinical risk factors as an aid in the diagnosis of osteoporosis and medical conditions leading to reduced bone density, and ultimately in the determination of fracture risk.

FDA product codes: KGI, MUA.

Rationale

Background
Bone Mineral Density

Risk factors for fracture include low bone mass, low bone strength, a personal history of fracture as an adult, or a history of fracture in a first-degree relative. Osteoporosis, defined as low bone mass leading to an increased risk of fragility fractures, is an extremely common disease in the elderly population due to age-related bone loss in both sexes and menopause-related bone loss in women. The World Health Organization (WHO) has diagnostic thresholds for osteoporosis based on bone mineral density (BMD) measurements compared with a T-score, which is the standard deviation difference between an individual's BMD and that of a young-adult reference population. Conditions that can cause or contribute to osteoporosis include lifestyle factors such as low intake of calcium, high intake of alcohol or cigarette smoking, and thinness. Other risk factors for osteoporosis include certain endocrine, hematologic, gastrointestinal tract and genetic disorders, hypogonadal states, and medications.
BMD can be measured using different techniques in a variety of central (i.e., hip or spine) or peripheral (i.e., wrist, finger, heel) sites. While BMD measurements are predictive of fragility fractures at all sites, central measurements of the hip and spine are the most predictive. Fractures of the hip and spine (i.e., vertebral fractures) are also considered to be the most clinically relevant. BMD is typically expressed as a T score.

The utility of screening BMD measurements can be established by demonstrating that screening identifies a population at increased risk of fracture and that, by treating those at-risk individuals, the rate of fractures is reduced thereby lowering fracture-related morbidity and mortality. These potential benefits of screening should outweigh the risks of screening (radiation exposure) or false positives (initiation of unnecessary treatment).

**Osteoporosis Treatment**

Treatment of osteoporosis includes both lifestyle measures (e.g., increased intake of calcium and vitamin D, exercise, smoking cessation) and pharmacologic measures. Current pharmacologic options include bisphosphonates such as alendronate (i.e., Fosamax), selective estrogen receptor modulators such as raloxifene (i.e., Evista), the recombinant human parathyroid hormone teriparatide (i.e., Forteo), and calcitonin. An updated 2014 systematic review funded by the Agency for Healthcare Research and Quality found good-quality evidence that bisphosphonates, denosumab, teriparatide, and raloxifene reduce fracture risk in postmenopausal women with BMD in the osteoporotic range and/or preexisting hip or vertebral fracture.1

The decision to perform bone density assessment should be based on an individual’s fracture risk profile and skeletal health assessment. In addition to age, sex, and BMD, risk factors included in the WHO Fracture Risk Assessment (FRAX) Tool2 are:

- Low body mass index;
- Parental history of hip fracture;
- Previous fragility fracture in adult life (i.e., occurring spontaneously or a fracture arising from trauma, which, in a healthy individual, would not have resulted in a fracture);
- Current smoking or 3 or more units of alcohol daily, where a unit is equivalent to a standard glass of beer (285 mL), a single measure of spirits (30 mL), a medium-sized glass of wine (120 mL), or 1 measure of an aperitif (60 mL);
- A disorder strongly associated with osteoporosis, which includes rheumatoid arthritis, type I (insulin-dependent) diabetes, osteogenesis imperfecta in adults, untreated long-standing hyperthyroidism, hypogonadism or premature menopause (<45 years), chronic malnutrition or malabsorption, and chronic liver disease;
- Current exposure to oral glucocorticoids or exposure to oral glucocorticoids for more than 3 months at a dose of prednisolone 5 mg daily or more (or equivalent doses of other glucocorticoids).

A 2011 joint position statement from the International Society for Clinical Densitometry and the International Osteoporosis Foundation included the official position that FRAX with BMD predicts risk of fracture better than clinical risk factors or BMD alone. In addition, the joint position statement indicated that measurements other than BMD or T score at the femoral neck by DXA are not recommended for use with FRAX.3 The FRAX tool does not include a recommendation about which patients to further assess or treat. The FRAX website states that this is a matter of clinical judgment and recommendations may vary by country.2

**Measurement Tools**

The following technologies are most commonly used to measure BMD.

**Dual X-Ray Absorptiometry**

Dual X-ray absorptiometry (DXA) is probably the most commonly used technique to measure BMD because of its ease of use, low radiation exposure, and its ability to measure BMD at both the hip and spine. DXA can also be used to measure peripheral sites, such as the wrist and...
finger. DXA generates 2 x-ray beams of different energy levels to scan the region of interest and measures the difference in attenuation as the low- and high-energy beams pass through the bone and soft tissue. The low-energy beam is preferentially attenuated by bone, while the high-energy beam is attenuated by both bone and soft tissue. This difference in attenuation between the 2 beams allows for correction for the irregular masses of soft tissue, which surround the spine and hip, and therefore the measurement of bone density at those sites.

Quantitative Computed Tomography
Quantitative computed tomography (QCT) depends on the differential absorption of ionizing radiation by calcified tissue and is used for central measurements only. Compared with DXA, QCT is less readily available and associated with relatively high radiation exposure and relatively high cost.

Ultrasound Densitometry
Ultrasound densitometry is a technique for measuring BMD at peripheral sites, typically the heel but also the tibia and phalanges. Compared with osteoporotic bone, normal bone demonstrates higher attenuation of the ultrasound wave and is associated with a greater velocity of the wave passing through bone. Ultrasound densitometry has no radiation exposure, and machines may be purchased for use in an office setting.

These techniques dominate BMD testing. Single- and dual-photon absorptiometry and radiographic absorptiometry are now rarely used and may be considered obsolete.

Note: Vertebral fracture assessment with DXA is addressed elsewhere (see Blue Shield of California Medical Policy: Vertebral Fracture Assessment with Densitometry).

Literature Review
Initial Measurement of Bone Mineral Density
Early versions of this evidence review were based in part on 1998 guidelines from the National Osteoporosis Foundation (NOF) and 2 Blue Cross Blue Shield Association Technology Evaluation Center (TEC) Assessments (1999, 2002). Because no data were available from randomized screening trials, the TEC Assessments focused on the evaluating the utility of bone mineral density (BMD) measurement in selecting patients for pharmacologic treatment to reduce risk of fracture. The TEC Assessments concluded that while both dual x-ray absorptiometry (DXA) and ultrasound densitometry were equivalent in predicting fracture risk, the 2 techniques appeared to identify different populations of at-risk patients. In addition, calcaneal ultrasound densitometry did not meet TEC criteria as a technique to predict response to pharmacologic therapy.

A 2005 meta-analysis of data from 9891 men and 29,082 women (from 12 cohort studies in Europe and Canada) found that BMD measurement at the femoral neck with DXA was a strong predictor of hip fractures for both sexes. At age 65 years, the relative risk for osteoporotic fractures increased by 1.4 (95% confidence interval [CI], 1.3 to 1.5) in men and by 1.4 (95% CI, 1.3 to 1.5) in women for each standard deviation decrease in BMD. Data for measurement of BMD using ultrasound and peripheral DXA were available from 3 cohorts. The predictive ability of these devices was less than that of DXA measurements at the femoral neck.

A systematic review of the evidence to update U.S. Preventive Services Task Force (USPSTF) recommendations on screening for osteoporosis was published in 2010. USPSTF reviewers stated that most DXA testing includes central DXA (i.e., measurements at the hip and lumbar spine) and that most randomized controlled trials (RCTs) of osteoporosis medications have had study inclusion criteria based on the findings of central DXA. Reviewers found that calcaneal quantitative ultrasound (QUS) measurement could also predict fracture but has a low correlation with DXA. Consequently, the clinical relevance of calcaneal QUS findings is unclear because medication studies have not selected patients based on QUS findings. In addition, the investigators reviewed large population-based cohorts on DXA screening and concluded that the predictive performance of DXA is similar for women and men.
In 2013, Gadam et al performed a cross-sectional analysis of data to assess the incremental predictive ability of BMD measured using DXA when added to the Fracture Risk Assessment (FRAX) Tool model. The study included 151 subjects (145 women, 6 men) older than 50 years of age without a prior osteoporosis diagnosis and who were not being treated with U.S. Food and Drug Administration (FDA)-approved medications for osteoporosis. Of the 151 subjects, predictions of 10-year fracture risk were identical for 127 (84%) patients when BMD was added to the FRAX model compared with the FRAX model without BMD. Of the subjects who had different risk estimates, the difference in risk prediction resulted in an additional 2 patients meeting the NOF threshold for treatment when BMD was added to the FRAX model. Age was the only risk factor that differed significantly between participants with identical versus different recommendations (p<0.001). Subjects who were younger (mean age, 64 years) were more likely to receive identical predictions than older subjects (mean age, 76 years). The study had a relatively small sample size and lacked longitudinal data on fractures. It provides some initial evidence that BMD may not add substantially to the predictive ability of the FRAX models, but these findings need to be corroborated in prospective studies with larger sample sizes.

Crandall et al (2015) reported results from 11,392 participants in the Women's Health Initiative (WHI) BMD Cohort, a prospective observational study of postmenopausal women with a mean follow-up of 8.5 years. Each standard deviation decline in lower BMD measured with central DXA was associated with higher wrist fracture risk, the adjusted hazard ratio (HR) being 1.7 (95% CI, 1.4 to 1.9) for femoral neck BMD and 1.5 (95% CI, 1.3 to 1.6) for lumbar spine BMD.

Cauley et al (2016) reported risk factors for hip fractures in 5994 men with a mean of 8.6 years of follow-up from the Osteoporotic Fractures in Men Study. Femoral neck BMD was measured using DXA. The incidence rate of hip fracture 33.4 per 1000 person-years in men with BMD T scores less than -2.5 who also had 4 or more risk factors, 14.5 per 1000 person-years in men age 80 years and older with 3 or more major comorbidities, and 0.88 per 1000 person-years in men age less than 70 years with zero comorbidities. Low BMD by World Health Organization classification (T score < -2.5) was highly associated with hip fracture (hazard ratio [HR], 3.3; 95% CI, 2.7 to 3.9) in a competing risk model after adjusting for several other fracture risk factors (e.g., age, previous fracture).

**Section Summary: Initial Measurement of Bone Mineral Density**

Central DXA is the most widely used method for measuring BMD. Several large studies have demonstrated a relation between fracture risk and BMD as measured by DXA in women and men. Most RCTs of the osteoporosis medications have had study inclusion criteria based on central DXA. These RCTs have shown that several osteoporosis medications are effective at reducing fracture risk in postmenopausal women with BMD in the osteoporotic range identified by central DXA and/or preexisting hip or vertebral fracture. This chain of evidence establishes that measuring BMD with central DXA improves health outcomes. There is less evidence for other methods of measuring BMD. BMD measured with other techniques may also be associated with fracture risk but has not been used to select participants for trials of osteoporosis medications.

**Repeat Measurement of BMD for Individuals without Osteoporosis on Initial Screen**

In the analysis from the WHI BMD cohort (2015) previously described, changes in central DXA were examined over a 3-year period. A total of 9172 women had baseline and year 3 measures of femoral neck BMD and 9216 women had baseline and year 3 measures of lumbar spine. Decrease in femoral neck BMD between baseline and year 3 was associated with increased risk of subsequent wrist fracture (HR=1.2; 95% CI, 1.0 to 1.3; p=0.03). Change in lumbar spine BMD was not associated with wrist fracture by year 3 (HR=1.1; 95% CI, 0.95 to 1.2; p=0.22).

Leslie et al (2016) reported on repeat BMD measurements in clinical practice for fracture risk assessment from a large clinical BMD database for Manitoba, Canada, of women and men ages 50 years and older from 1990 to 2009. BMD was measured in the hip, lumbar spine, and femoral neck using DXA. A total of 50,215 participants had 1 BMD measurement, 14,619 had a second measurement, 4722 had a third measurement, and 1500 had a fourth measurement. The
mean time between measurements was 4.2 years. Total hip BMD was predictive of major osteoporotic fracture at each time point. The association between BMD and major osteoporotic fracture was similar for the first and second BMD measurements: adjusted hazard ratios per standard deviation were 1.5 (95% CI, 1.3 to 1.6) and 1.6 (95% CI, 1.5 to 1.8), respectively. The hazard ratio for the second measurement was similar when stratified by preceding change in BMD or osteoporosis therapy.

A 2013 study by Berry et al did not find that changes in BMD 4 years after initial measurement added substantially to the prediction of fracture risk in untreated subjects. The authors included 210 women and 492 men (mean age, 75 years) from the Framingham Osteoporosis Study, a population-based cohort study, who had 2 BMD measurements (mean, 3.7 years apart) and did not have a hip fracture before the second test. BMD of the femoral neck was measured using a dual-photon absorptiometer from 1987 through 1991 and DXA from 1992 through 1999. Median follow-up was 9.6 years after the second BMD test. During this time, 76 individuals experienced a hip fracture and 113 had a major osteoporotic fracture (fracture of the hip, spine, forearm, or shoulder). In receiver operating curve analyses, adding repeat BMD to a model containing baseline BMD did not meaningfully improve the model's ability to predict hip fracture (area under the curve [AUC], 0.72; 95% CI, 0.66 to 0.79). When percent change in BMD was used, the AUC was 0.71 (95% CI, 0.65 to 0.78) in a model including only baseline BMD and 0.68 (95% CI, 0.62 to 0.75) in a model including percent change in BMD.

A 2012 multicenter prospective study by Gourlay et al have provided data on the optimal bone density screening interval in a large cohort of women with normal BMD measured by DXA or osteopenia at an initial screen. The investigators included 4957 women ages 67 years or older who had BMD data at 2 or more examinations or at 1 examination before a competing risk event (hip or clinical vertebral fracture). The study only included women who were candidates for osteoporosis screening. Other individuals, such as those with osteoporosis at baseline or with a history of a hip or clinical vertebral fracture, were excluded, because they would already be candidates for pharmacologic treatment. The primary study outcome was the estimated time interval for 10% of participants to make the transition from normal BMD or osteopenia at baseline to osteoporosis before a hip or clinical vertebral fracture occurred and before starting osteoporosis treatment. For women with normal BMD at baseline, the estimated BMD testing interval was 16.8 years (95% CI, 11.5 to 24.6 years). The study found that the estimated BMD testing interval was 17.3 years (95% CI, 13.9 to 21.5 years) for women with mild osteopenia at baseline, 4.7 years (95% CI, 4.2 to 5.2 years) with moderate osteopenia, and 1.1 years (95% CI, 1.0 to 1.3 years) for women with advanced osteopenia.

Longitudinal changes in BMD measured by central DXA, as a function of age and antiresorptive agents, were reported in 2008 by the Canadian Multicentre Osteoporosis Study Research Group. Among a random selection of 9423 men and women from 9 major Canadian cities, 4433 women and 1935 men (cumulatively 70%) were included for analysis. The subjects were 25 years of age or older with BMD measurements repeated 3 or 5 years apart; they tended to have better health than the 30% who did not have longitudinal data and who were excluded from analysis. Results showed that annual rates of bone loss, measured at the hip or femoral neck, increased between 25 and 85 years of age in women who were not on antiresorptive therapy, with accelerated periods of bone loss around menopausal transition (age range, 40-54 years) and after 70 years of age. Antiresorptive therapy, which primarily consisted of hormone replacement when the study began in 1995, was associated with attenuated bone loss across all age ranges. For women 50 to 79 years of age, the average loss in BMD over a 5-year period was 3.2% in nonusers of antiresorptive therapy and 0.2% in women who used antiresorptive therapy. The pattern in men was generally similar to that of women with 2 exceptions: BMD loss began earlier in men and the rate of change remained relatively constant between 40 and 70 years of age. Notably, BMD at the lumbar spine did not parallel measurements at the hip and femoral neck, suggesting that vertebral bone density assessment may be obscured by degenerative changes in the spine or other artifact. The report concluded that "although current guidelines recommend that measurements of bone density be repeated once every 2
to 3 years, our data suggest that, at this rate of testing, the average person would exhibit change well below the margin of error, especially since only 25% of women experienced a loss of bone density that exceeded 5% over 5 years."

In 2009, Frost et al published a prognostic model to determine the optimal screening interval for a subject without osteoporosis (defined as T score > -2.5). They used prospective population-based data collected from 1008 women and 750 men who were nonosteoporotic at baseline; participants received BMD screening every 2 years and had a median follow-up of 7.1 years. The prognostic model included 2 variables: age and initial BMD score. Results were stratified for these variable, presented tabularly, showing estimated time to reach 20% risk of sustaining a fracture or osteoporosis. Most of the time estimates were 3 years or longer. The estimated shortest time to reach a 20% risk was 2.4 years; this was for women 80 years and older with a baseline T score of -2.2. For a typical screening candidate (a 65-year-old woman with a baseline T score of -1.0), the estimated time to reach a 10% risk of fracture was 3.8 years and to reach a 20% risk of fracture was 6.5 years. Overall, the study suggested that the 3- to 5-year time interval for repeat measurement of BMD in people who tested normal is reasonable but that an individualized model could result in longer or shorter recommended retesting intervals.

A 2007 study by Hillier et al did not find that follow-up central DXA BMD measurements 8 years after a baseline screen provided substantial value in terms of predicting risk of fracture. The study included 4124 women ages 65 years and older and assessed total hip BMD at initial and follow-up screening examinations. In analyses adjusted for age and weight change, the initial and repeat BMD measurements had similar associations with fracture risk; this included risk of vertebral fractures, non-vertebral fractures, and hip fractures. Stratifying the analysis by initial BMD T scores (i.e., normal, osteopenic, osteoporotic) did not alter findings.

Section Summary: Repeat Measurement of BMD for Individuals without Osteoporosis on Initial Screen
Scant research has been done on the frequency of BMD monitoring for osteoporosis. The available research has evaluated repeat measurement with central DXA. Evidence on whether repeat measurements add to risk prediction compared with a single measurement is mixed. A longitudinal study suggests that a 3- to 5-year interval for repeat measurement of BMD in people who tested normal at baseline is reasonable, although the optimal interval may differ depending on risk factors.

Serial Measurement of Central BMD to Monitor Response to Bisphosphonate Treatment
In 2009, Bell et al conducted a secondary analysis of data from the Fracture Intervention Trial (FIT), which randomized 6459 postmenopausal women with low BMD to treatment with bisphosphonates or to placebo; women underwent annual bone density scans. The investigators estimated between-person (treatment-related) variation and within-person (measurement-related) variation in hip and spine BMD measured by central DXA over time to assess the value of repeat BMD scans for monitoring response to treatment. After 3 years, the mean cumulative increase in hip BMD was 0.30 g/cm² in the alendronate group compared with a mean decrease of 0.012 g/cm² in the placebo group. Moreover, 97.5% of patients treated with alendronate had increases in hip BMD of at least 0.019 g/cm², suggesting that there was a clinically significant response. However, the study also found large within-person variability in year-to-year bone density measurements. The average within-person variation in BMD measurement was 0.013 g/cm² relative to the placebo, which was substantially higher than the average annual increase in BMD in the alendronate group, 0.0085 g/cm². This finding suggests that the precision of BMD measurement is not reliable from year to year, and thus annual retesting may not be clinically useful. Additional studies would be needed to determine the optimal time interval for rescreening after starting bisphosphonate treatment.

Serial Measurement of Central BMD to Monitor Discontinuation of Bisphosphonate Treatment
In 2014, Bauer et al reported on fracture risk prediction among women who discontinued alendronate after 4 to 5 years of treatment in the FLEX (Fracture Intervention Trial Long-term...
Extension) study. Women ages 61 to 86 years who had been treated with alendronate were randomized to 5 more years of alendronate or to placebo. A prior report of this study (2006) found that although hip BMD decreased in the placebo group, rates of fracture were similar between the group randomized to placebo and the group that continued on bisphosphonate therapy. It should be noted that alendronate has a half-life in humans that is estimated to exceed 10 years. During the 5 years of placebo treatment, 94 (22%) of 437 women experienced 1 or more symptomatic fractures; most (87%) occurred after 1 year. Post hoc analysis found that older age and lower hip (but not spine) DXA at time of discontinuation were significantly related to increased fracture risk; however, changes in BMD between the beginning of discontinuation to years 1 and 3 were not.

Summary of Evidence
For individuals who are eligible for screening of bone mineral density (BMD) based on risk factor assessment who receive dual x-ray absorptiometry (DXA) analysis of central sites (hip or spine), the evidence includes large cohort studies, observational studies, and systematic reviews. Relevant outcomes are disease-specific survival, morbid events, functional outcomes, health status measures, quality of life, hospitalizations, medication use, and resource utilization. BMD measurements with central DXA identify individuals at increased risk of fracture. There is sufficient evidence that osteoporosis medications are effective at reducing fracture risk in postmenopausal women with BMD in the osteoporotic range identified by central DXA. Therefore, a chain of evidence establishes that screening BMD with central DXA is likely to improve health outcomes. Evidence to support serial or repeat measurement of BMD is less compelling; nonetheless, the available evidence and the consensus of clinical evidence-based guidelines support at least a 2-year interval in BMD measurement to monitor response to pharmacologic therapy. Finally, available evidence suggests that at least a 3- to 5-year timeframe is reasonable for repeat measurement of BMD in individuals who initially tested normal and to monitor pharmacologic therapy. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who are eligible for screening of BMD based on risk factor assessment who receive ultrasound densitometry, or quantitative computed tomography, or DXA analysis of peripheral sites, the evidence includes observational studies and systematic reviews. Relevant outcomes are disease-specific survival, morbid events, functional outcomes, health status measures, quality of life, hospitalizations, medication use, and resource utilization. These technologies are not commonly used for BMD measurements in practice and no studies have shown that they can select patients who benefit from treatment for osteoporosis. There is little to no evidence on the usefulness of repeat measurement of BMD using these techniques. The evidence is insufficient to determine the effects of the technology on health outcomes.

Supplemental Information
Clinical Input from Physician Specialty Societies and Academic Medical Centers
While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

In response to requests, input was received from 4 physician specialty societies (7 reviewers) and 2 academic medical centers while this evidence review was under review in 2008. In addition, 7 unsolicited letters were received through 2 additional physician specialty societies. Reviewers agreed with the evidence review statement that an initial bone mineral density (BMD) test may be medically necessary. They also recommended an interval of 3 to 5 years between measurements in subjects who previously tested normal, depending on risk factors. Reviewers considered serial measurement of BMD important to guide treatment decisions (e.g., continuing or changing medication).
Based on the consensus of clinical opinion on the value of the information provided by monitoring treatment response, serial BMD measurements (at least a 2-year interval) may be considered appropriate when this information will impact patient care. It should be noted that, with the margin of error of BMD measurements with dual x-ray absorptiometry, questions remain about the interval over which a clinically significant change can be observed. The minimal clinically significant change also raises concerns about the potential for overinterpretation of small fluctuations with repeat testing.

Practice Guidelines and Position Statements
American College of Obstetricians and Gynecologists
In 2012 (reaffirmed 2014), the American College of Obstetricians and Gynecologists (ACOG) updated its guidelines on managing osteoporosis in women.22 The guidelines recommended that bone mineral density (BMD) screening should begin for all women at age 65 years. In addition, ACOG recommended screening for women younger than 65 years in whom the Fracture Risk Assessment (FRAX) Tool indicates a 10-year risk of osteoporotic fracture of at least 9.3%. Alternatively, ACOG recommended BMD screening women in younger than 65 or with any of the following risk factors (they are similar, but not identical to risk factors in FRAX):

- Personal medical history of a fragility fracture
- Parental medical history of hip fracture
- Weight less than 127 lb
- Medical causes of bone loss (i.e., medications or disease)
- Current smoker
- Alcoholism
- Rheumatoid arthritis

For women who begin medication treatment for osteoporosis, a repeat BMD is recommended 1 to 2 years later to assess effectiveness. If BMD is improved or stable, additional BMD testing (in the absence of new risk factors) is not recommended. The guideline notes that it generally takes 18 to 24 months to document a clinically meaningful change in BMD and thus a 2-year interval after treatment initiation is preferred to 1 year.

The guidelines do not specifically discuss repeat BMD screening for women who have a normal finding on the initial test.

Routine BMD screening is not recommended for newly menopausal women as a “baseline” screen.

National Osteoporosis Foundation
The National Osteoporosis Foundation (NOF) updated its practice guidelines in 2014.23 NOF guidelines recommended that all postmenopausal women and men ages 50 and older be evaluated clinically for osteoporosis risk to determine the need for BMD testing.

Indications for BMD testing included:

- “[W]omen age 65 and older and men age 70 and older” regardless of clinical risk factors
- “[P]ostmenopausal women and men above age 50-69, based on risk factors profile”
- “[P]ostmenopausal women and men age 50 and older who have had an adult age fracture...”
- “Adults with a condition ... or taking a medication ... associated with low bone mass or bone loss”

NOF stated that measurements for monitoring patients should be performed in accordance with medical necessity, expected response, and in consideration of local regulatory requirements. NOF recommended that repeat BMD assessments generally agree with Medicare guidelines of every 2 years, but recognized that testing more frequently may be warranted in certain clinical situations.

NOF also indicated that:
"Central DXA [dual x-ray absorptiometry] assessment of the hip or lumbar spine is the ‘gold standard’ for serial assessment of BMD. Biological changes in bone density are small compared to the inherent error in the test itself, and interpretation of serial bone density studies depends on appreciation of the smallest change in BMD that is beyond the range of error of the test. This least significant change (LSC) varies with the specific instrument used, patient population being assessed, measurement site, technologist’s skill with patient positioning and test analysis, and the confidence intervals used. Changes in the BMD of less than 3-6 % at the hip and 2-4 % at the spine from test to test may be due to the precision error of the testing itself."

American College of Physicians
The 2008 guidelines from the American College of Physicians (ACP) recommended that clinicians periodically perform individualized assessment of risk factors for osteoporosis in men older than 50 years (grade: strong recommendation; moderate-quality evidence).24 Factors that increase the risk for osteoporosis in men included age (>70 years), low body mass index, weight loss, physical inactivity, corticosteroid use, androgen deprivation therapy, and previous fragility fracture. ACP recommended that clinicians obtain DXA for men who are at increased risk for osteoporosis and are candidates for drug therapy (grade: strong recommendation; moderate-quality evidence). The guidelines indicated that bone density measurement with DXA is the accepted reference standard for diagnosing osteoporosis in men; because treatment trials have not measured the effectiveness of therapy for osteoporosis diagnosed by ultrasound densitometry rather than DXA, the role of ultrasound in diagnosis remains uncertain. This evidence review found no studies that evaluated the optimal intervals for repeated screening by using BMD measurement with DXA in men.

American College of Radiology
Practice guidelines from the American College of Radiology, last amended in 2016,25 state that BMD measurement is indicated whenever a clinical decision is likely to be directly influenced by the result of the test. Indications for DXA included but were not limited to the following patient populations:

1. All women age 65 years and older and men age 70 years and older (asymptomatic screening)
2. Women younger than age 65 years who have additional risk for osteoporosis, based on medical history and other findings. Additional risk factors for osteoporosis include:
   a. Estrogen deficiency
   b. A history of maternal hip fracture that occurred after the age of 50 years
   c. Low body mass (less than 127 lb or 57.6 kg)
   d. History of amenorrhea (more than 1 year before age 42 years)
3. Women younger than age 65 years or men younger than age 70 years who have additional risk factors, including:
   a. Current use of cigarettes
   b. Loss of height, thoracic kyphosis
4. Individuals of any age with bone mass osteopenia, or fragility fractures on imaging studies such as radiographs, CT [computed tomography], or MRI [magnetic resonance imaging]
5. Individuals age 50 years and older who develop a wrist, hip, spine, or proximal humerus fracture with minimal or no trauma, excluding pathologic fractures
6. Individuals of any age who develop 1 or more insufficiency fractures
7. Individuals being considered for pharmacologic therapy for osteoporosis.
8. Individuals being monitored to:
   a. Assess the effectiveness of osteoporosis drug therapy.
   b. Follow-up medical conditions associated with abnormal BMD.

International Society for Clinical Densitometry
The 2013 update of the International Society for Clinical Densitometry guidelines recommended bone density testing in the following patients26:
• “Women age 65 and older
• For post-menopausal women younger than age 65 a bone density test is indicated if
  they have a risk factor for low bone mass fracture such as;
  o Low body weight
  o Prior fracture
  o High risk medication use
  o Disease or condition associated with bone loss.
• Women during the menopausal transition with clinical risk factors for fracture, such as low
  bone weight, prior fracture or high-risk medication use.
• Men aged 70 and older.
• Men under < 70 years old if they have a risk factors for low bone mass such as;
  o Low body weight
  o Prior fracture
  o High risk medication use
  o Disease or condition associated with bone loss.
• Adults with a fragility fracture.
• Adults with a disease or condition associated with low bone mass or bone loss...
• Anyone being considered for pharmacologic therapy.
• Anyone being treated, to monitor treatment effect.
• Anyone not receiving therapy in whom evidence of bone loss would lead to treatment.”

**American Association of Clinical Endocrinologists et al**

In 2016, the American Association of Clinical Endocrinologists and American College of
Endocrinology issued updated joint guidelines on the diagnosis and treatment of
postmenopausal osteoporosis.27 The guidelines listed the potential uses for BMD measurements in
postmenopausal women as:
• “Screening for osteoporosis
• Establishing the severity of osteoporosis or bone loss...
• Determining fracture risk...
• Identifying candidates for pharmacologic intervention
• Assessing changes in bone density over time...
• Enhancing acceptance of, and perhaps adherence with, treatment
• Assessing skeletal consequences of diseases, conditions, or medications known to cause bone loss”

**North American Menopause Society**

The North American Menopause Society issued a 2010 position statement,28 which indicated
that fracture is the most significant risk of low bone density. The statement also concluded that
BMD is an important determinant of fracture risk, especially in women 65 years and older.

**U.S. Preventive Services Task Force Recommendations**

The U.S. Preventive Services Task Force (USPSTF) updated its recommendations on screening for
osteoporosis with bone density measurements in January 2011.29 USPSTF recommended
“screening for osteoporosis in women aged 65 years or older and in younger women whose risk
of fracture is equal to or greater than that of a 65-year-old white woman who has no additional
risk factors.” This represents a change from the previous (2002) version, in which there was no
specific recommendation on screening in women younger than 65 years old. The supporting
document notes that there are multiple instruments to predict risk for low BMD and that the
USPSTF used FRAX.2 The updated USPSTF recommendations stated that the scientific evidence is
“insufficient” to recommend for or against routine osteoporosis screening in men. The Task Force
did not recommend specific screening tests but said that the most commonly used tests are DXA
of the hip and lumbar spine and quantitative ultrasound of the calcaneus.

USPSTF recommended the following on BMD screening intervals: “A lack of evidence exists
about the optimal intervals for repeat screening and whether repeated screening is necessary in
a woman with normal BMD. Because of limitations in the precision of testing, a minimum of 2
years may be needed to reliably measure a change in BMD; however, longer intervals may be necessary to improve fracture risk prediction.”

USPSTF recommendations for osteoporosis screening are in the process of being updated as of February 2017.

Medicare National Coverage
The Centers for Medicare and Medicaid pays for a screening bone mass measurement (BMM) once every 2 years (at least 23 months have passed since the month the last covered BMM was performed). When medically necessary, Medicare may pay for more frequent BMMs. Examples include, but are not limited to, monitoring beneficiaries on long-term glucocorticoid (steroid) therapy of more than 3 months, and confirming baseline BMMs to permit monitoring of beneficiaries in the future.

Conditions for coverage of BMM can be found in chapter 15, section 80.5 of Pub. 100-02, Medicare Benefit Policy Manual. Medicare covers BMM under the following conditions:

1. “Is ordered by the physician or qualified nonphysician practitioner who is treating the beneficiary following an evaluation of the need for a BMM and determination of the appropriate BMM to be used….

2. Is performed under the appropriate level of physician supervision as defined in 42 CFR 410.32(b).

3. Is reasonable and necessary for diagnosing and treating the condition of a beneficiary who meets the conditions described in §80.5.6.

4. In the case of an individual being monitored to assess the response to or efficacy of an FDA-approved osteoporosis drug therapy, is performed with a dual-energy x-ray absorptiometry system (axial skeleton).

5. In the case of any individual who meets the conditions of 80.5.6 and who has a confirmatory BMM, is performed by a dual-energy x-ray absorptiometry system (axial skeleton) if the initial BMM was not performed by a dual-energy x-ray absorptiometry system (axial skeleton). A confirmatory baseline BMM is not covered if the initial BMM was performed by a dual-energy x-ray absorptiometry system (axial skeleton).”

Ongoing and Unpublished Clinical Trials
A search of ClinicalTrials.gov in February 2017 did not identify any ongoing or unpublished trials that would likely influence this review.

References


**Documentation for Clinical Review**

Please provide the following documentation (if/when requested):

- History and physical from the prescribing MD including:
  - Previous treatment and response, and clinical risk factors for osteoporosis-related fracture
  - Additional reports including: Previous bone mineral density measurement, x-ray reports and laboratory reports

**Post Service**

- DXA report for date of service billed

**Coding**

This Policy relates only to the services or supplies described herein. Benefits may vary according to product design; therefore, contract language should be reviewed before applying the terms of the Policy. Inclusion or exclusion of codes does not constitute or imply member coverage or provider reimbursement.

**MN/IE**

The following services may be considered medically necessary in certain instances and investigational in others. Services may be considered medically necessary when policy criteria are met. Services may be considered investigational when the policy criteria are not met or when the code describes application of a product in the position statement that is investigational.

<table>
<thead>
<tr>
<th>Type</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT®</td>
<td>0508T</td>
<td>Pulse-echo ultrasound bone density measurement resulting in indicator of axial bone mineral density tibia <strong>(Code effective 7/1/2018)</strong></td>
</tr>
<tr>
<td></td>
<td>76977</td>
<td>Ultrasound bone density measurement and interpretation, peripheral site(s), any method</td>
</tr>
<tr>
<td></td>
<td>77078</td>
<td>Computed tomography, bone mineral density study, 1 or more sites, axial skeleton (e.g., hips, pelvis, spine)</td>
</tr>
<tr>
<td></td>
<td>77080</td>
<td>Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (e.g., hips, pelvis, spine)</td>
</tr>
<tr>
<td></td>
<td>77081</td>
<td>Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; appendicular skeleton (peripheral) (e.g., radius, wrist, heel)</td>
</tr>
</tbody>
</table>
### Type Code Description

<table>
<thead>
<tr>
<th>Type</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone Mineral Density Studies</td>
<td>78350</td>
<td>Bone density (bone mineral content) study, 1 or more sites; single photon absorptiometry</td>
</tr>
<tr>
<td>Bone Mineral Density Studies</td>
<td>78351</td>
<td>Bone density (bone mineral content) study, 1 or more sites; dual photon absorptiometry, 1 or more sites</td>
</tr>
</tbody>
</table>

#### HCPCS

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>G0130</td>
<td>Single energy x-ray absorptiometry (SEXA) bone density study, one or more sites; appendicular skeleton (peripheral) (e.g., radius, wrist, heel)</td>
</tr>
</tbody>
</table>

#### ICD-10 Procedure

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>BP48ZZ1</td>
<td>Ultrasonography of Right Shoulder, Densitometry</td>
</tr>
<tr>
<td>BP49ZZ1</td>
<td>Ultrasonography of Left Shoulder, Densitometry</td>
</tr>
<tr>
<td>BP4GZZ1</td>
<td>Ultrasonography of Right Elbow, Densitometry</td>
</tr>
<tr>
<td>BP4HZZ1</td>
<td>Ultrasonography of Left Elbow, Densitometry</td>
</tr>
<tr>
<td>BP4LZZ1</td>
<td>Ultrasonography of Right Wrist, Densitometry</td>
</tr>
<tr>
<td>BP4MZZ1</td>
<td>Ultrasonography of Left Wrist, Densitometry</td>
</tr>
<tr>
<td>BP4NZZ1</td>
<td>Ultrasonography of Right Hand, Densitometry</td>
</tr>
<tr>
<td>BP4PZZ1</td>
<td>Ultrasonography of Left Hand, Densitometry</td>
</tr>
<tr>
<td>BQ00ZZ1</td>
<td>Plain Radiography of Right Hip, Densitometry</td>
</tr>
<tr>
<td>BQ01ZZ1</td>
<td>Plain Radiography of Left Hip, Densitometry</td>
</tr>
<tr>
<td>BQ03ZZ1</td>
<td>Plain Radiography of Right Femur, Densitometry</td>
</tr>
<tr>
<td>BQ04ZZ1</td>
<td>Plain Radiography of Left Femur, Densitometry</td>
</tr>
<tr>
<td>BR00ZZ1</td>
<td>Plain Radiography of Cervical Spine, Densitometry</td>
</tr>
<tr>
<td>BR07ZZ1</td>
<td>Plain Radiography of Thoracic Spine, Densitometry</td>
</tr>
<tr>
<td>BR09ZZ1</td>
<td>Plain Radiography of Lumbar Spine, Densitometry</td>
</tr>
<tr>
<td>BR0GZZ1</td>
<td>Plain Radiography of Whole Spine, Densitometry</td>
</tr>
</tbody>
</table>

### Policy History

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

<table>
<thead>
<tr>
<th>Effective Date</th>
<th>Action</th>
<th>Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>07/02/2009</td>
<td>New Policy Policies combined: Bone Mineral Density Screening for Vertebral Fracture with Dual X-ray Absorptiometry (DEXA)</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>07/08/2010</td>
<td>Policy Revision Testing interval revised</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>01/12/2011</td>
<td>Policy Revision - Testing interval revised</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>04/01/2011</td>
<td>Policy revision with position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>03/13/2012</td>
<td>Coding Update</td>
<td>Administrative Review</td>
</tr>
<tr>
<td>01/01/2015</td>
<td>Coding Update</td>
<td>Administrative Review</td>
</tr>
<tr>
<td>08/31/2015</td>
<td>Policy title change from Bone Mineral Density and Vertebral Fracture Assessment Policy revision with position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>03/01/2017</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>05/01/2017</td>
<td>Policy revision with position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>05/01/2018</td>
<td>Coding update</td>
<td>Administrative Review</td>
</tr>
</tbody>
</table>

### Definitions of Decision Determinations

**Medically Necessary**: A treatment, procedure, or drug is medically necessary only when it has been established as safe and effective for the particular symptoms or diagnosis, is not investigational or experimental, is not being provided primarily for the convenience of the patient or the provider, and is provided at the most appropriate level to treat the condition.
**Investigational/Experimental:** A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.

**Split Evaluation:** Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.

---

**Prior Authorization Requirements (as applicable to your plan)**

Within five days before the actual date of service, the provider must confirm with Blue Shield that the member’s health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member’s eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions.

Questions regarding the applicability of this policy should be directed to the Prior Authorization Department. Please call (800) 541-6652 or visit the provider portal at www.blueshieldca.com/provider.

**Disclaimer:** This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. Blue Shield of California may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member contracts may differ in their benefits. Blue Shield reserves the right to review and update policies as appropriate.